BeiGene Ltd (BGNE)
190.94
-3.62
(-1.86%)
USD |
NASDAQ |
Nov 22, 10:23
BeiGene Total Liabilities (Quarterly): 2.395B for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.395B |
| June 30, 2024 | 2.346B |
| March 31, 2024 | 2.307B |
| December 31, 2023 | 2.268B |
| September 30, 2023 | 1.762B |
| June 30, 2023 | 1.930B |
| March 31, 2023 | 1.799B |
| December 31, 2022 | 1.996B |
| September 30, 2022 | 2.071B |
| June 30, 2022 | 2.076B |
| March 31, 2022 | 2.136B |
| December 31, 2021 | 2.403B |
| September 30, 2021 | 1.929B |
| June 30, 2021 | 1.917B |
| March 31, 2021 | 1.817B |
| December 31, 2020 | 1.732B |
| September 30, 2020 | 1.270B |
| June 30, 2020 | 1.357B |
| March 31, 2020 | 1.240B |
| December 31, 2019 | 633.93M |
| Date | Value |
|---|---|
| September 30, 2019 | 586.83M |
| June 30, 2019 | 579.05M |
| March 31, 2019 | 549.55M |
| December 31, 2018 | 496.04M |
| September 30, 2018 | 425.20M |
| June 30, 2018 | 427.19M |
| March 31, 2018 | 350.20M |
| December 31, 2017 | 362.25M |
| September 30, 2017 | 284.57M |
| June 30, 2017 | 203.80M |
| March 31, 2017 | 68.31M |
| December 31, 2016 | 52.91M |
| September 30, 2016 | 47.59M |
| June 30, 2016 | 31.18M |
| March 31, 2016 | 22.13M |
| December 31, 2015 | 42.44M |
| September 30, 2015 | 35.53M |
| June 30, 2015 | 27.05M |
| December 31, 2014 | 27.85M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
633.93M
Minimum
Dec 2019
2.403B
Maximum
Dec 2021
1.869B
Average
1.930B
Median
Total Liabilities (Quarterly) Benchmarks
| Theravance Biopharma Inc | 170.45M |
| Merck & Co Inc | 72.97B |
| Bristol-Myers Squibb Co | 76.47B |
| Zai Lab Ltd | 317.68M |
| Halozyme Therapeutics Inc | 1.665B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 5.831B |
| Shareholders Equity (Quarterly) | 3.436B |
| Debt to Equity Ratio | 0.306 |
| Current Ratio | 1.931 |
| Net Debt Paydown Yield | -0.35% |